



Tests you can trust

Pco g : XXXXXXXX

Fcv g : XXXXXXXXXX

VguVC ungf : Aarogyam D Pro Package

Tgr qtv"Uvcwu : Complete Report



First National Diagnostic Chain
to have 100% of its Labs with
NABL Accreditation#



Accredited by



NABL From 2005#



ISO 9001: 2015 - From 2015



CAP From 2011

Your reports are digitally verifiable

Scan the QR code inside the report
to check authenticity of reported values

QR code will remain active for 30 days from report release date




98% Reports
released within
06 Hours
of sample reaching the lab*



9 out of 10 Doctors Trust
that Thyrocare
reports are
Accurate & Reliable*



1200+
Tests & Profiles



Temperature-
Controlled
Sample Logistics



Unique Barcode
Tracking



Fully Automated
Machines Inspected
Daily



Abnormal Values
Re-Checked Twice



Reports Verified By Expert
MD Pathologists Stationed
at Every Lab

Patient Name : XXXXXXXXXXXXX
 Referred By : XXXXXXXXXXXXX
 Sample Collected At : XXXXXXXXXXXXX

Tests Done : AAROGYAM D PRO PACKAGE

Report Availability Summary

Note: Please refer to the table below for status of your tests.

✔ 19 Ready
⚠ 0 Ready with Cancellation
🔄 0 Processing
✖ 0 Cancelled in Lab

TEST DETAILS

REPORT STATUS

TEST DETAILS	REPORT STATUS
AAROGYAM D PRO PACKAGE	Ready ✔
CHLORIDE	Ready ✔
25-OH VITAMIN D (TOTAL)	Ready ✔
FREE TRIIODOTHYRONINE (FT3)	Ready ✔
FREE THYROXINE (FT4)	Ready ✔
HOMOCYSTEINE	Ready ✔
HIGH SENSITIVITY C-REACTIVE PROTEIN (HS-CRP)	Ready ✔
Lipoprotein (a) [Lp(a)]	Ready ✔
PHOSPHOROUS	Ready ✔
SODIUM	Ready ✔
TOTAL IGE	Ready ✔
TSH - ULTRASENSITIVE	Ready ✔
VITAMIN B-12	Ready ✔
HBA PROFILE	Ready ✔
HEMOGRAM - 6 PART (DIFF)	Ready ✔
LIVER FUNCTION TESTS	Ready ✔
IRON DEFICIENCY PROFILE	Ready ✔
KIDPRO	Ready ✔
LIPID PROFILE	Ready ✔
APOLIPROTEIN RATIO	Ready ✔

Patient Name : XXXXXXXXXXXXX

Tests Done : AAROGYAM D PRO PACKAGE

Referred By : XXXXXXXXXXXXX

Sample Collected At : XXXXXXXXXXXXX

Tests Outside Reference Range

Note: Please refer to the table below for tests outside reference range.

Test Name	Observed Value	Units	Bio. Ref. Interval.
COMPLETE HEMOGRAM			
HEMATOCRIT(PCV)	33.6	%	40.0-50.0
HEMOGLOBIN	10.4	g/dL	13.0-17.0
LYMPHOCYTE	17.4	%	20-40
MEAN CORP.HEMO.CONC(MCHC)	31	g/dL	31.5-34.5
MEAN CORPUSCULAR HEMOGLOBIN(MCH)	26.8	pg	27.0-32.0
RED CELL DISTRIBUTION WIDTH (RDW-CV)	15.4	%	11.6-14
RED CELL DISTRIBUTION WIDTH - SD(RDW-SD)	48.9	fL	39-46
TOTAL RBC	3.88	X 10 ⁶ /μL	4.5-5.5
LIPID			
LDL / HDL RATIO	0.9	Ratio	1.5-3.5
TC/ HDL CHOLESTEROL RATIO	2.2	Ratio	3 - 5
RENAL			
CREATININE - SERUM	0.7	mg/dL	0.72-1.18
VITAMIN			
25-OH VITAMIN D (TOTAL)	11.62	ng/mL	30-100
VITAMIN B-12	981	pg/mL	211-911



First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

Patient Name : XXXXXXXXXXXXX
 Referred By : XXXXXXXXXXXXX
 Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
 Sample Received on (SRT) : XXXXXXXXXXXXX
 Report Released on (RRT) : XXXXXXXXXXXXX
 Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
HbA1c	H.P.L.C	5.1	%
Bio. Ref. Interval. :			
As per ADA Guidelines		Guidance For Known Diabetics	
Below 5.7% : Normal		Below 6.5% : Good Control	
5.7% - 6.4% : Prediabetic		6.5% - 7% : Fair Control	
>=6.5% : Diabetic		7.0% - 8% : Unsatisfactory Control	
		>8% : Poor Control	

Method : Fully Automated H.P.L.C method


AVERAGE BLOOD GLUCOSE (ABG) CALCULATED 100 mg/dL

Bio. Ref. Interval. :

90 - 120 mg/dl : Good Control
121 - 150 mg/dl : Fair Control
151 - 180 mg/dl : Unsatisfactory Control
> 180 mg/dl : Poor Control

Method : Derived from HBA1c values

Please correlate with clinical conditions.



Tests Done : HBA PROFILE,HEMOGRAM

Report Remarks : Labcode:2303104033/IT001

Doctor 1 Sign

Doctor 2 Sign



First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation*

Patient Name : XXXXXXXXXXXXX
 Referred By : XXXXXXXXXXXXX
 Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
 Sample Received on (SRT) : XXXXXXXXXXXXX
 Report Released on (RRT) : XXXXXXXXXXXXX
 Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	METHODOLOGY	VALUE	UNITS	Bio. Ref. Interval.
HEMOGLOBIN	SLS-Hemoglobin Method	10.4	g/dL	13.0-17.0
Hematocrit (PCV)	CPH Detection	33.6	%	40.0-50.0
Total RBC	HF & EI	3.88	X 10⁶/μL	4.5-5.5
Mean Corpuscular Volume (MCV)	Calculated	86.6	fL	83.0-101.0
Mean Corpuscular Hemoglobin (MCH)	Calculated	26.8	pq	27.0-32.0
Mean Corp.Hemo. Conc (MCHC)	Calculated	31	g/dL	31.5-34.5
Red Cell Distribution Width - SD (RDW-SD)	Calculated	48.9	fL	39-46
Red Cell Distribution Width (RDW - CV)	Calculated	15.4	%	11.6-14
RED CELL DISTRIBUTION WIDTH INDEX (RDWI)	Calculated	343.7	-	*Refer Note below
MENTZER INDEX	Calculated	22.3	-	*Refer Note below
TOTAL LEUCOCYTE COUNT (WBC)	HF & FC	7.77	X 10³ / μL	4.0 - 10.0
DIFFERENTIAL LEUCOCYTE COUNT				
Neutrophils Percentage	Flow Cytometry	75.2	%	40-80
Lymphocytes Percentage	Flow Cytometry	17.4	%	20-40
Monocytes Percentage	Flow Cytometry	2.7	%	2-10
Eosinophils Percentage	Flow Cytometry	3.9	%	1-6
Basophils Percentage	Flow Cytometry	0.5	%	0-2
Immature Granulocyte Percentage (IG%)	Flow Cytometry	0.3	%	0-0.5
Nucleated Red Blood Cells %	Flow Cytometry	0.1	%	0.0-5.0
ABSOLUTE LEUCOCYTE COUNT				
Neutrophils - Absolute Count	Calculated	5.84	X 10 ³ / μL	2.0-7.0
Lymphocytes - Absolute Count	Calculated	1.35	X 10 ³ / μL	1.0-3.0
Monocytes - Absolute Count	Calculated	0.21	X 10 ³ / μL	0.2 - 1.0
Basophils - Absolute Count	Calculated	0.04	X 10 ³ / μL	0.02 - 0.1
Eosinophils - Absolute Count	Calculated	0.3	X 10 ³ / μL	0.02 - 0.5
Immature Granulocytes (IG)	Calculated	0.02	X 10 ³ / μL	0-0.3
Nucleated Red Blood Cells	Calculated	0.01	X 10 ³ / μL	0.0-0.5
PLATELET COUNT				
Mean Platelet Volume (MPV)	HF & EI	260	X 10 ³ / μL	150-410
Platelet Distribution Width (PDW)	Calculated	10.3	fL	6.5-12
Platelet to Large Cell Ratio (PLCR)	Calculated	11.2	fL	9.6-15.2
Platelet to Large Cell Ratio (PLCR)	Calculated	26.6	%	19.7-42.4
Plateletcrit (PCT)	Calculated	0.27	%	0.19-0.39

*Note - Mentzer index (MI), RDW-CV and RDWI are hematological indices to differentiate between Iron Deficiency Anemia (IDA) and Beta Thalassemia Trait (BTT). MI >13, RDWI >220 and RDW-CV >14 more likely to be IDA. MI <13, RDWI <220, and RDW-CV <14 more likely to be BTT. Suggested Clinical correlation. BTT to be confirmed with HB electrophoresis if clinically indicated.

Method : Fully automated bidirectional analyser (6 Part Differential SYSMEX XN-1000)

(Reference : *FC- flowcytometry, *HF- hydrodynamic focussing, *EI- Electric Impedance, *Hb- hemoglobin, *CPH- Cumulative pulse height)

Tests Done : HBA PROFILE,HEMOGRAM

Report Remarks : Labcode:2303104033/IT001

Doctor 1 Sign

Doctor 2 Sign



First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

Patient Name : XXXXXXXXXXXXX
 Referred By : XXXXXXXXXXXXX
 Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
 Sample Received on (SRT) : XXXXXXXXXXXXX
 Report Released on (RRT) : XXXXXXXXXXXXX
 Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
HOMOCYSTEINE	PHOTOMETRY	< 15	µmol/L

Bio. Ref. Interval. :-

- Normal Levels : <15 µmol/L
- Mild Hyperhomocysteinemia : 15-30 µmol/L
- Moderate Hyperhomocysteinemia : 30-100 µmol/L
- Severe Hyperhomocysteinemia : >100 µmol/L

Clinical Significance:

Homocysteine is linked to increased risk of premature coronary artery disease, stroke and thromboembolism. Moreover, alzheimers disease, osteoporosis, venous thrombosis, schizophrenia, cognitive deficiency and pregnancy complications also elevates Homocysteine levels. The results should be interpreted in conjunction with clinical history and other findings.

High Values:

Elevated homocysteine levels might be due to increasing age, genetic traits, drugs, renal dysfunction and dietary deficiency of vitamins or smoking. To lower your homocysteine, eat more green vegetables, stop smoking, alcohol. Folic acid helps lowering elevated levels.

Specifications:

Kit Validation Reference:

Eikelboom JW, et al Ann Intern Med 131 : 363-75 (1999)
<https://www.healthline.com/health/homocysteine-levels>

Please correlate with clinical conditions.

Method:- SMALL MOLECULE CAPTURE TECHNOLOGY (SMT)

Tests Done : AAROGYAM D PRO PACKAGE

Report Remarks : Labcode:2303104034/IT001

Doctor 1 Sign

Doctor 2 Sign



Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703. 9870666333 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation#

Patient Name : XXXXXXXXXXXXX
Referred By : XXXXXXXXXXXXX
Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
Sample Received on (SRT) : XXXXXXXXXXXXX
Report Released on (RRT) : XXXXXXXXXXXXX
Sample Type | Barcode : XXXXXXXXXXXXX

Table with 4 columns: TEST NAME, TECHNOLOGY, VALUE, UNITS. Row 1: 25-OH VITAMIN D (TOTAL), C.L.I.A, 11.62, ng/mL. Row 2: Bio. Ref. Interval. :-

DEFICIENCY : <20 ng/ml || INSUFFICIENCY : 20-<30 ng/ml
SUFFICIENCY : 30-100 ng/ml || TOXICITY : >100 ng/ml

Clinical Significance:

Vitamin D is a fat soluble vitamin that has been known to help the body absorb and retain calcium and phosphorous; both are critical for building bone health. Decrease in vitamin D total levels indicate inadequate exposure of sunlight, dietary deficiency, nephrotic syndrome. Increase in vitamin D total levels indicate Vitamin D intoxication.

Specifications: Precision: Intra assay (%CV):5.3%, Inter assay (%CV):11.9% ; Sensitivity:3.2 ng/ml.

Kit Validation Reference: Holick MF. Vitamin D Deficiency. N Engl J Med. 2007;357:266-81.

Please correlate with clinical conditions.

Method:- Fully Automated Chemi Luminescent Immuno Assay

Tests Done : AAROGYAM D PRO PACKAGE

Report Remarks : Labcode:2303104034/IT001

Doctor 1 Sign

Doctor 2 Sign



First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

Patient Name : XXXXXXXXXXXXX
 Referred By : XXXXXXXXXXXXX
 Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
 Sample Received on (SRT) : XXXXXXXXXXXXX
 Report Released on (RRT) : XXXXXXXXXXXXX
 Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
APOLIPOPROTEIN - A1 (APO-A1) Bio. Ref. Interval. : Male : 86 - 152 Female : 94 - 162 Method : FULLY AUTOMATED RATE IMMUNOTURBIDIMETRY - BECKMAN COULTER	IMMUNOTURBIDIMETRY	< 119	mg/dL
APOLIPOPROTEIN - B (APO-B) Bio. Ref. Interval. : Male : 56 - 145 Female : 53 - 138 Method : FULLY AUTOMATED RATE IMMUNOTURBIDIMETRY - BECKMAN COULTER	IMMUNOTURBIDIMETRY	< 101	mg/dL
APO B / APO A1 RATIO (APO B/A1) Bio. Ref. Interval. : Male : 0.40 - 1.26 Female : 0.38 - 1.14 Clinical Significance : <ul style="list-style-type: none"> • Apolipoprotein B is a more potent and independent predictor of Coronary artery disease (CAD) than LDL Cholesterol. • Apolipoprotein A1 is one of the apoproteins of HDL and is inversely related to risk of CAD. • The Apolipoprotein studies help in monitoring risk of restenosis in patients with myocardial infarction, Coronary bypass surgery etc. • An increased ratio of Apo B to A1 beyond the defined normal range is indicative of CAD risk. • All results have to be interpreted in Conjunction with clinical history and other findings. Method : Derived from serum Apo A1 and Apo B values	CALCULATED	0.8	Ratio

Please correlate with clinical conditions.

Tests Done : AAROGYAM D PRO PACKAGE

Report Remarks : Labcode:2303104034/IT001

Doctor 1 Sign

Doctor 2 Sign



Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703. 9870666333 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

Patient Name : XXXXXXXXXXXXX
 Referred By : XXXXXXXXXXXXX
 Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
 Sample Received on (SRT) : XXXXXXXXXXXXX
 Report Released on (RRT) : XXXXXXXXXXXXX
 Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
TOTAL IGE Bio. Ref. Interval. :-	C.L.I.A	< 50	IU/mL

Age	Value
0 - 1 Year	1.40 - 52.3
1 - 4 Years	0.40 - 351.6
5 - 10 Years	0.50 - 393
11 - 15 Years	1.90 - 170
Adults	< 158

Clinical significance:

Quantitative measurement of serum IgE when integrated with other clinical indicator, can provide useful information for the differential clinical diagnosis of Atopic and Non-Atopic disease. Patients with Atopic disease, including allergic asthma, allergic rhinitis and Atopic dermatitis commonly have moderately elevated serum IgE levels. However, a serum IgE level that is within the range of normally expected values does not rule out a limited set of IgE allergy. For diagnostic purpose, results should always be assessed in conjunction with the patients medical history, clinical examination and other findings.

Specifications:

Precision: Intra assay (%CV): 7.2 %, Inter assay (%CV): 5.4 %; Sensitivity: 1.5 IU/ml

Kit validation references

Kjellman N-IM, Johansson SGO, Roth A. Serum IgE levels in healthy children by a sandwich technique. (Prist). Clin Allergy 1976: 6:51-9.

Please correlate with clinical conditions.

Method:- TWO SITE SANDWICH IMMUNOASSAY

Tests Done : AAROGYAM D PRO PACKAGE

Report Remarks : Labcode:2303104034/IT001

Doctor 1 Sign

Doctor 2 Sign



Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703. 9870666333 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

Patient Name : XXXXXXXXXXXXX
 Referred By : XXXXXXXXXXXXX
 Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
 Sample Received on (SRT) : XXXXXXXXXXXXX
 Report Released on (RRT) : XXXXXXXXXXXXX
 Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
VITAMIN B-12	C.L.I.A	981	pg/mL
Bio. Ref. Interval. :-			

Normal : 211 - 911 pg/ml

Clinical significance :

Vitamin B12 or cyanocobalamin, is a complex corrinoid compound found exclusively from animal dietary sources, such as meat, eggs and milk. It is critical in normal DNA synthesis, which in turn affects erythrocyte maturation and in the formation of myelin sheath. Vitamin-B12 is used to find out neurological abnormalities and impaired DNA synthesis associated with macrocytic anemias. For diagnostic purpose, results should always be assessed in conjunction with the patients medical history, clinical examination and other findings.


Specifications: Intra assay (%CV):5.0%, Inter assay (%CV):9.2 %;Sensitivity:45 pg/ml

Kit Validation reference:

Chen IW, Sperling MI, Heminger LA. Vitamin B12. In: Pesce AJ, Kaplan LA, eds. Methods in Clinical Chemistry. St. Louis: CV Mosby; 1987:569-73.

Please correlate with clinical conditions.

Method:- COMPETITIVE CHEMI LUMINESCENT IMMUNO ASSAY



Tests Done : AAROGYAM D PRO PACKAGE

Report Remarks : Labcode:2303104034/IT001

Doctor 1 Sign

Doctor 2 Sign



First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

Patient Name : XXXXXXXXXXXXX
 Referred By : XXXXXXXXXXXXX
 Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
 Sample Received on (SRT) : XXXXXXXXXXXXX
 Report Released on (RRT) : XXXXXXXXXXXXX
 Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
Lipoprotein (a) [Lp(a)] Bio. Ref. Interval. :-	IMMUNOTURBIDIMETRY	< 14.95	mg/dL

Adults : < 30.0 mg/dl

Clinical Significance:

Determination of LPA may be useful to guide management of individuals with a family history of CHD or with existing disease. The levels of LPA in the blood depends on genetic factors; The range of variation in a population is relatively large and hence for diagnostic purpose, results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

Specifications:


Precision %CV :- Intra assay %CV- 4.55% , Inter assay %CV-0.86 %

Kit Validation Reference:

Tietz NW,Clinical Guide to Laboratory Tests Philadelphia WB. Saunders 1995 : 442-444

Please correlate with clinical conditions.

Method:- LATEX ENHANCED IMMUNOTURBIDIMETRY



Tests Done : AAROGYAM D PRO PACKAGE

Report Remarks : Labcode:2303104034/IT001

Doctor 1 Sign

Doctor 2 Sign



First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

Patient Name : XXXXXXXXXXXXX
 Referred By : XXXXXXXXXXXXX
 Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
 Sample Received on (SRT) : XXXXXXXXXXXXX
 Report Released on (RRT) : XXXXXXXXXXXXX
 Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
HIGH SENSITIVITY C-REACTIVE PROTEIN (HS-CRP) Bio. Ref. Interval. :-	IMMUNOTURBIDIMETRY	1.1	mg/L

- < 1.00 - Low Risk
- 1.00 - 3.00 - Average Risk
- >3.00 - 10.00 - High Risk
- > 10.00 - Possibly due to Non-Cardiac Inflammation

Disclaimer: Persistent unexplained elevation of HSCRP >10 should be evaluated for non-cardiovascular etiologies such as infection, active arthritis or concurrent illness.

Clinical significance:

High sensitivity C- reactive Protein (HSCRP) can be used as an independent risk marker for the identification of Individuals at risk for future cardiovascular Disease. A coronary artery disease risk assessment should be based on the average of two hs-CRP tests, ideally taken two weeks apart.

Kit Validation Reference:

- 1.Clinical management of laboratory data in medical practice 2003-3004, 207(2003).
- 2.Tietz : Textbook of Clinical Chemistry and Molecular diagnostics :Second edition :Chapter 47:Page no.1507- 1508.

Please correlate with clinical conditions.

Method:- FULLY AUTOMATED LATEX AGGLUTINATION – BECKMAN COULTER

Tests Done : AAROGYAM D PRO PACKAGE

Report Remarks : Labcode:2303104034/IT001

Doctor 1 Sign

Doctor 2 Sign




First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

Patient Name : XXXXXXXXXXXXX
Referred By : XXXXXXXXXXXXX
Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
Sample Received on (SRT) : XXXXXXXXXXXXX
Report Released on (RRT) : XXXXXXXXXXXXX
Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
IRON Bio. Ref. Interval. : Male : 65 - 175 Female : 50 - 170 Method : Ferrozine method without deproteinization	PHOTOMETRY	98	µg/dL
TOTAL IRON BINDING CAPACITY (TIBC) Bio. Ref. Interval. : Male: 225 - 535 µg/dl Female: 215 - 535 µg/dl Method : Spectrophotometric Assay	PHOTOMETRY	334	µg/dL
% TRANSFERRIN SATURATION Bio. Ref. Interval. : 13 - 45 Method : Derived from IRON and TIBC values	CALCULATED	29	%
UNSAT.IRON-BINDING CAPACITY(UIBC) Bio. Ref. Interval. : 162 - 368 Method : SPECTROPHOTOMETRIC ASSAY	PHOTOMETRY	236.2	µg/dL

Please correlate with clinical conditions.



Tests Done : AAROGYAM D PRO PACKAGE

Report Remarks : Labcode:2303104034/IT001

Doctor 1 Sign

Doctor 2 Sign



First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation#

Patient Name : XXXXXXXXXXXXX
 Referred By : XXXXXXXXXXXXX
 Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT): XXXXXXXXXXXXX
 Sample Received on (SRT) : XXXXXXXXXXXXX
 Report Released on (RRT) : XXXXXXXXXXXXX
 Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS	Bio. Ref. Interval.
TOTAL CHOLESTEROL	PHOTOMETRY	123	mg/dL	< 200
HDL CHOLESTEROL - DIRECT	PHOTOMETRY	56	mg/dL	40-60
LDL CHOLESTEROL - DIRECT	PHOTOMETRY	53.5	mg/dL	< 100
TRIGLYCERIDES	PHOTOMETRY	120	mg/dL	< 150
TC/ HDL CHOLESTEROL RATIO	CALCULATED	2.2	Ratio	3 - 5
TRIG / HDL RATIO	CALCULATED	2.12	Ratio	< 3.12
LDL / HDL RATIO	CALCULATED	0.9	Ratio	1.5-3.5
HDL / LDL RATIO	CALCULATED	1.05	Ratio	> 0.40
NON-HDL CHOLESTEROL	CALCULATED	66.2	mg/dL	< 160
VLDL CHOLESTEROL	CALCULATED	23.94	mg/dL	5 - 40

Please correlate with clinical conditions.

Method :

- CHOL - Cholesterol Oxidase, Esterase, Peroxidase
- HCHO - Direct Enzymatic Colorimetric
- LDL - Direct Measure
- TRIG - Enzymatic, End Point
- TC/H - Derived from serum Cholesterol and Hdl values
- TRI/H - Derived from TRIG and HDL Values
- LDL/ - Derived from serum HDL and LDL Values
- HD/LD - Derived from HDL and LDL values.
- NHDL - Derived from serum Cholesterol and HDL values
- VLDL - Derived from serum Triglyceride values

***REFERENCE RANGES AS PER NCEP ATP III GUIDELINES:**

TOTAL CHOLESTEROL	(mg/dl)	HDL	(mg/dl)	LDL	(mg/dl)	TRIGLYCERIDES	(mg/dl)
DESIRABLE	<200	LOW	<40	OPTIMAL	<100	NORMAL	<150
BORDERLINE HIGH	200-239	HIGH	>60	NEAR OPTIMAL	100-129	BORDERLINE HIGH	150-199
HIGH	>240			BORDERLINE HIGH	130-159	HIGH	200-499
				HIGH	160-189	VERY HIGH	>500
				VERY HIGH	>190		

Alert !!! 10-12 hours fasting is mandatory for lipid parameters. If not, values might fluctuate.

Tests Done : AAROGYAM D PRO PACKAGE

Report Remarks : Labcode:2303104034/IT001

Doctor 1 Sign

Doctor 2 Sign



First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

Patient Name : XXXXXXXXXXXXX
Referred By : XXXXXXXXXXXXX
Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
Sample Received on (SRT) : XXXXXXXXXXXXX
Report Released on (RRT) : XXXXXXXXXXXXX
Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS	Bio. Ref. Interval.
ALKALINE PHOSPHATASE	PHOTOMETRY	105.1	U/L	45-129
BILIRUBIN - TOTAL	PHOTOMETRY	0.45	mg/dL	0.3-1.2
BILIRUBIN -DIRECT	PHOTOMETRY	0.14	mg/dL	0 - 0.20
BILIRUBIN (INDIRECT)	CALCULATED	0.31	mg/dL	0-0.9
GAMMA GLUTAMYL TRANSFERASE (GGT)	PHOTOMETRY	13.4	U/L	< 55
ASPARTATE AMINOTRANSFERASE (SGOT)	PHOTOMETRY	24.3	U/L	< 35
ALANINE TRANSAMINASE (SGPT)	PHOTOMETRY	32.9	U/L	< 45
SGOT / SGPT RATIO	CALCULATED	0.74	Ratio	< 2
PROTEIN - TOTAL	PHOTOMETRY	6.98	gm/dL	5.7-8.2
ALBUMIN - SERUM	PHOTOMETRY	4.14	gm/dL	3.2-4.8
SERUM GLOBULIN	CALCULATED	2.84	gm/dL	2.5-3.4
SERUM ALB/GLOBULIN RATIO	CALCULATED	1.46	Ratio	0.9 - 2

Please correlate with clinical conditions.

Method :

- ALKP - Modified IFCC method
- BILT - Diazonium salt DPD method
- BILD - Diazonium salt DPD method
- BILI - Derived from serum Total and Direct Bilirubin values
- GGT - Modified IFCC method
- SGOT - IFCC* Without Pyridoxal Phosphate Activation
- SGPT - IFCC* Without Pyridoxal Phosphate Activation
- OT/PT - Derived from SGOT and SGPT values.
- PROT - Biuret Method
- SALB - Albumin Bcg¹method (Colorimetric Assay Endpoint)
- SEGB - DERIVED FROM SERUM ALBUMIN AND PROTEIN VALUES
- A/GR - Derived from serum Albumin and Protein values

Tests Done : AAROGYAM D PRO PACKAGE

Report Remarks : Labcode:2303104034/IT001

Doctor 1 Sign

Doctor 2 Sign



First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

Patient Name : XXXXXXXXXXXXX
 Referred By : XXXXXXXXXXXXX
 Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
 Sample Received on (SRT) : XXXXXXXXXXXXX
 Report Released on (RRT) : XXXXXXXXXXXXX
 Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
PHOSPHOROUS	PHOTOMETRY	4.24	mg/dL
Bio. Ref. Interval. : Adults : 2.4 - 5.1 mg/dL Children : 4.0 - 7.0 mg/dL Clinical Significance: In plasma and serum the majority of phosphate exists in the inorganic form (Pi), approximately 15% bound to protein and the remainder in complexes and free forms. Serum phosphate concentrations are dependent on diet and variation in the secretion of hormones such as Parathyroid Hormone (PTH). Specifications: Precision %CV :- Intra assay %CV- 1.55% , Inter assay %CV-2.99% , Sensitivity:-0.10 mmol/L Kit Validation Reference: Young DS. Effects of drugs on clinical laboratory tests, 5th ed. AACC Press, 2000. Method : UNREDUCED PHOSPHOMOLYBDATE METHOD			

Please correlate with clinical conditions.

Tests Done : AAROGYAM D PRO PACKAGE

Report Remarks : Labcode:2303104034/IT001

Doctor 1 Sign

Doctor 2 Sign



First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

Patient Name : XXXXXXXXXXXXX
Referred By : XXXXXXXXXXXXX
Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
Sample Received on (SRT) : XXXXXXXXXXXXX
Report Released on (RRT) : XXXXXXXXXXXXX
Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS	Bio. Ref. Interval.
FREE TRIIODOTHYRONINE (FT3)	C.L.I.A	<3.2	pg/mL	1.7-4.2
FREE THYROXINE (FT4)	C.L.I.A	<1.31	ng/dL	0.7-1.8
TSH - ULTRASENSITIVE	C.M.I.A	<2.92	μIU/mL	0.35-4.94

The Biological Reference Ranges is specific to the age group. Kindly correlate clinically.

Method :

FT3,FT4 - Competitive Chemi Luminescent Immuno Assay
USTSH - Fully Automated Chemi Luminescent Microparticle Immunoassay

Disclaimer : Results should always be interpreted using the reference range provided by the laboratory that performed the test. Different laboratories do tests using different technologies, methods and using different reagents which may cause difference. In reference ranges and hence it is recommended to interpret result with assay specific reference ranges provided in the reports. To diagnose and monitor therapy doses, it is recommended to get tested every time at the same Laboratory.

Tests Done : AAROGYAM D PRO PACKAGE

Report Remarks : Labcode:2303104034/IT001

Doctor 1 Sign

Doctor 2 Sign



First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

Patient Name : XXXXXXXXXXXXX
 Referred By : XXXXXXXXXXXXX
 Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
 Sample Received on (SRT) : XXXXXXXXXXXXX
 Report Released on (RRT) : XXXXXXXXXXXXX
 Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
CHLORIDE Bio. Ref. Interval. : ADULTS: 98-107 MMOL/L	I.S.E - INDIRECT	101	mmol/L
Clinical Significance : An increased level of blood chloride (called hyperchloremia) usually indicates dehydration, but can also occur with other problems that cause high blood sodium, such as Cushing syndrome or kidney disease. Hyperchloremia also occurs when too much base is lost from the body (producing metabolic acidosis) or when a person hyperventilates (causing respiratory alkalosis). A decreased level of blood chloride (called hypochloremia) occurs with any disorder that causes low blood sodium. Hypochloremia also occurs with congestive heart failure, prolonged vomiting or gastric suction, Addison disease, emphysema or other chronic lung diseases (causing respiratory acidosis), and with loss of acid from the body (called metabolic alkalosis).			
Method : ION SELECTIVE ELECTRODE - INDIRECT			
SODIUM Bio. Ref. Interval. : Adults: 136-145 mmol/l	I.S.E - INDIRECT	137	mmol/L
Method : ION SELECTIVE ELECTRODE - INDIRECT			
Please correlate with clinical conditions.			

Tests Done : AAROYAM D PRO PACKAGE

Report Remarks : Labcode:2303104034/IT001

Doctor 1 Sign

Doctor 2 Sign



First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

Patient Name : XXXXXXXXXXXXX
Referred By : XXXXXXXXXXXXX
Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
Sample Received on (SRT) : XXXXXXXXXXXXX
Report Released on (RRT) : XXXXXXXXXXXXX
Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS	Bio. Ref. Interval.
BLOOD UREA NITROGEN (BUN)	PHOTOMETRY	12.6	mg/dL	7.94 - 20.07
CREATININE - SERUM	PHOTOMETRY	0.7	mg/dL	0.72-1.18
BUN / Sr.CREATININE RATIO	CALCULATED	18	Ratio	9:1-23:1
UREA (CALCULATED)	CALCULATED	26.96	mg/dL	Adult : 17-43
UREA / SR.CREATININE RATIO	CALCULATED	38.52	Ratio	< 52
CALCIUM	PHOTOMETRY	9.62	mg/dL	8.8-10.6
URIC ACID	PHOTOMETRY	6.8	mg/dL	4.2 - 7.3

Please correlate with clinical conditions.

Method :

- BUN - Kinetic UV Assay.
- SCRE - Creatinine Enzymatic Method
- B/CR - Derived from serum Bun and Creatinine values
- UREAC - Derived from BUN Value.
- UR/CR - Derived from UREA and Sr.Creatinine values.
- CALC - Arsenazo III Method, End Point.
- URIC - Uricase / Peroxidase Method

Tests Done : AAROGYAM D PRO PACKAGE

Report Remarks : Labcode:2303104034/IT001

Doctor 1 Sign

Doctor 2 Sign



First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation[#]

Patient Name : XXXXXXXXXXXXX
Referred By : XXXXXXXXXXXXX
Sample Collected At : XXXXXXXXXXXXX

Sample Collected on (SCT) : XXXXXXXXXXXXX
Sample Received on (SRT) : XXXXXXXXXXXXX
Report Released on (RRT) : XXXXXXXXXXXXX
Sample Type | Barcode : XXXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
EST. GLOMERULAR FILTRATION RATE (eGFR) Bio. Ref. Interval. :-	CALCULATED	134	mL/min/1.73 m ²

> = 90 : Normal
60 - 89 : Mild Decrease
45 - 59 : Mild to Moderate Decrease
30 - 44 : Moderate to Severe Decrease
15 - 29 : Severe Decrease
<15 : Kidney Failure

Clinical Significance

The normal serum creatinine reference interval does not necessarily reflect a normal GFR for a patient. Because mild and moderate kidney injury is poorly inferred from serum creatinine alone. Thus, it is recommended for clinical laboratories to routinely estimate glomerular filtration rate (eGFR), a "gold standard" measurement for assessment of renal function, and report the value when serum creatinine is measured for patients 18 and older, when appropriate and feasible. It cannot be measured easily in clinical practice, instead, GFR is estimated from equations using serum creatinine, age, race and sex. This provides easy to interpret information for the doctor and patient on the degree of renal impairment since it approximately equates to the percentage of kidney function remaining. Application of CKD-EPI equation together with the other diagnostic tools in renal medicine will further improve the detection and management of patients with CKD.

Reference

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.

Please correlate with clinical conditions.

Method:- 2021 CKD EPI Creatinine Equation

~~ End of report ~~

Tests Done : AAROGYAM D PRO PACKAGE

Report Remarks : Labcode:2303104034/IT001

Doctor 1 Sign

Doctor 2 Sign

CONDITIONS OF REPORTING

- v The reported results are for information and interpretation of the referring doctor only.
- v It is presumed that the tests performed on the specimen belong to the patient; named or identified.
- v Results of tests may vary from laboratory to laboratory and also in some parameters from time to time for the same patient.
- v Should the results indicate an unexpected abnormality, the same should be reconfirmed.
- v Only such medical professionals who understand reporting units, reference ranges and limitations of technologies should interpret results.
- v This report is not valid for medico-legal purpose.
- v Neither Thyrocare, nor its employees/representatives assume: (a) any liability, responsibility for any loss or damage that may be incurred by any person as a result of presuming the meaning or contents of the report, (b) any claims of any nature whatsoever arising from or relating to the performance of the requested tests as well as any claim for indirect, incidental or consequential damages. The total liability, in any case, of Thyrocare shall not exceed the total amount of invoice for the services provided and paid for.
- v Thyrocare Discovery video link :- <https://youtu.be/nbdYeRgYyQc>

EXPLANATIONS

- v Majority of the specimen processed in the laboratory are collected by Pathologists and Hospitals we call them as "Clients".
- v **Name** - The name is as declared by the client and recored by the personnel who collected the specimen.
- v **Ref.Dr** - The name of the doctor who has recommended testing as declared by the client.
- v **Labcode** - This is the accession number in our laboratory and it helps us in archiving and retrieving the data.
- v **Barcode** - This is the specimen identity number and it states that the results are for the specimen bearing the barcode (irrespective of the name).
- v **SCP** - Specimen Collection Point - This is the location where the blood or specimen was collected as declared by the client.
- v **SCT** - Specimen Collection Time - The time when specimen was collected as declared by the client.
- v **SRT** - Specimen Receiving Time - This time when the specimen reached our laboratory.
- v **RRT** - Report Releasing Time - The time when our pathologist has released the values for Reporting.
- v **Reference Range** - Means the range of values in which 95% of the normal population would fall.

SUGGESTIONS

- v Values out of reference range requires reconfirmation before starting any medical treatment.
- v Retesting is needed if you suspect any quality shortcomings.
- v Testing or retesting should be done in accredited laboratories.
- v For suggestions, complaints, clinical support or feedback, write to us at customersupport@thyrocare.com or call us on **022-3090 0000**

Preventive Healthcare is now at your fingertips!



Download Thyroapp Now



Launching

Jaanch

For a closer look at your health with

Doctor-Curated Specialised Packages All Under One Roof

Heart

Fever

Cancer

Women's - Reproductive Health

Thyroid

Diabetes

STDs

Skin Care

Hair Fall

Thyrocare
Tests you can trust

* T&C Apply, #As on 5th December 2024 (Applicable for all company owned labs except Bhagalpur & Vijayawada),

* As per survey on doctors' perception of laboratory diagnostics (IJARIIT, 2023), -Mumbai Reference Lab is CAP Accredited